Paper des Monats
18.11.2022 Desiree: dose escalation of everolimus published
We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.
02.09.2022 August 2022 : Neoadjuvant durvalumab improves survival in early triple-negative breast cancer despite a modest pCR increase – follow-up data from GeparNuevo trial
We are pleased to inform you that long-term outcomes from GeparNuevo trial have been published in Annals of Oncology.
31.07.2022 July 2022: HER2-positive breast cancer patients with brain metastases have the best prognosis compared to other tumor subtypes
We are pleased to inform you that a subanalysis of HER2-positive breast cancer patients with brain metastasis from the BMBC registry has been published in ESMO Open.
30.06.2022 June 2022: Pregnancy does not impact the effectiveness of chemotherapy for breast cancer.
We are pleased to inform you that outcome of pregnant breast cancer patients treated with chemotherapy versus non-pregnant controls has been published in European Journal of Cancer
31.05.2022 May 2022: Effect of denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy for primary breast cancer – results from GeparX trial
We are pleased to inform you that primary results from GeparX trial have been published in JAMA Oncology.